HARBIN, China, Dec. 28, 2011 /PRNewswire-Asia/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (NASDAQ:
CSKI), a leading fully integrated pharmaceutical company in
the People's Republic of China
("PRC"), today announced that Hongyu
Pan, the Company's Chief Financial Officer, will be leaving
the Company effective December 22,
2011 for personal reasons. His resignation was not a result
of any disputes or disagreements with the Company on any matter
relating to its operations, policies or practices. The Company has
initiated a search for a new Chief Financial Officer and will make
an announcement as soon as a candidate has been chosen.
"We truly appreciate Mr. Pan's contributions during his tenure
and wish him the best in all of his future endeavors," said Mr.
Jianping Li, China Sky One Medical's
General Manager and a Board Director.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The
Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its
wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and
Technology Company, Harbin First Bio-Engineering Company Limited,
Heilongjiang Tianlong Pharmaceutical, Inc. and Peng Lai Jin Chuang
Pharmaceutical Company, the Company manufactures and distributes
over-the-counter pharmaceutical products, which make up its major
revenue source. For more information, visit
http://www.cski.com.cn.
Safe Harbor Statement
Certain of the statements made in the press release
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
can be identified by the use of forward- looking terminology such
as "believe,"
"expect," "may,"
"will," "should,"
"project," "plan,"
"seek," "intend,"
or "anticipate" or the negative
thereof or comparable terminology. Such statements typically
involve risks and uncertainties and may include financial
projections or information regarding the
Company's daily operation and
management change. Actual results could differ
materially from the expectations reflected in such forward-looking
statements as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions in The
People's Republic of
China, variations in cash flow, reliance on collaborative
retail partners and on new product development, variations in new
product development, risks associated with rapid technological
change, the potential of introduced or undetected flaws and defects
in products, consumer acceptance of new products to be
launched and other risk factors detailed in reports filed
with the Securities and Exchange Commission from time to
time.
Investor Relations Contact:
China Sky One Medical
Queenie Liu, Corporate Secretary
Email: ir@cski.com.cn
CCG Investor Relations
David Rudnick
Tel: +1-646-626-4172
Email: david.rudnick@ccgir.com
Website: www.ccgirasia.com
Mabel Zhang, Vice President
Tel: +1-310-954-1353
Email: mabel.zhang@ccgir.com
SOURCE China Sky One Medical, Inc.